Home›Trial›NCT07122986
NCT07122986Phase 1RECRUITING

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

Study Summary

This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.

Conditions
Healthy Participants
Interventions / Drugs
E coli vaccine 1 Dose AE coli vaccine 1 Dose BE coli vaccine 2E coli vaccine 3E coli Vaccine 4 Dose AE coli Vaccine 4 Dose BE coli Vaccine 4 Dose CE coli Vaccine 5 Dose AE coli Vaccine 5 Dose BPlacebo
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F33/100
Study Details
Enrollment310 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.190561+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 310 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company F (33/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.